Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Data by

Global Data

25

Revenue 2014

Merck KGaA

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Merck KGaA's 2013 sales performance.

Fresenius Kabi buys Akorn and Merck's biosimilar businesses

Fresenius Kabi buys Akorn and Merck's biosimilar businesses

Fresenius Kabi has beefed up its pharmaceuticals division with deals to acquire US generic drugmaker Akorn for $4.3bn and Merck KGaA's fledgling biosimilars business for up to 670m ($730m). ... Adding in Merck's biosimilars business takes it right back

Roche claims another FDA green light for Tecentriq

Roche claims another FDA green light for Tecentriq Bristol-Myers Squibb and Merck &Co, which both reached the market ahead of Roche's drug for other cancer indications. ... The reality is that in time the three drugs - along with newer entrants such as Merck KGaA and Pfizer's Bavencio (avelumab) - will

Deal Watch March 2017

Deal Watch March 2017 Merck KGaA has partnered its product M1095 (ALX-0761), for plaque psoriasis, to Avillion.

The Medicines Company strengthens board of directors

The Medicines Company strengthens board of directors Prior to joining ARIAD, Panayiotopoulos served as president of EMD Serono - the North American biopharmaceutical business of Merck KGaA - after serving as president of Merck Serono, Tokyo.

Roche sets disruptive price for new MS drug Ocrevus in US

Roche sets disruptive price for new MS drug Ocrevus in US Firm will significantly under cut rivals like Merck's Rebif. Roche has claimed US approval for its much anticipated new multiple sclerosis (MS) drug Ocrevus, and is pricing it at a ... Ocrevus' clinical profile has already caught the attention of MS

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ()

Global Data Data by GlobalData

GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health Unlimited

Health Unlimited is part of the Unlimited group (http://www.unlimitedgroup.com), bringing together consultants and discipline experts from across the group and...

Latest intelligence

Bowel Cancer Awareness Month
Synergy Vision are supporting Bowel Cancer Awareness Month. Bowel cancer is one of most common cancers diagnosed in the UK, but with early diagnosis and treatment, most cases can be...
Anthill_icon_Green_18_Dialogue.png
The right way to capture customer data
Digital communication should be a two-way process with information flowing backwards and forwards between you and healthcare professionals. That digital technology enables HCPs to give feedback is a big part...
Anthill_icon_Green_17_Multi-channel.png
Can you access your own content?
The rapid development of multichannel communication opens new opportunities to provide high-value experiences for healthcare professionals and gives you more places than ever to tell your product story. But unless...

Infographics